Navigation Links
Islet Sciences Announces Strategic Alliance with Spring Point Project
Date:8/7/2012

NEW YORK, Aug. 7, 2012 /PRNewswire/ -- Islet Sciences, Inc., (OTCBB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced that it has signed a strategic alliance with Spring Point Project.

Spring Point Project's team has unique experience under the current Good Manufacturing Practices (cGMP) required by U.S. Food and Drug Administration regulations. Thanks to a substantial donation from the Diabetes Resource and Wellness Foundation, Spring Point Project's 21,000-square-foot facility – the Diabetes Research and Wellness Islet Resource Facility – was opened in February 2007.

"This partnership is an important piece in our strategy to initiate our Islet transplantation trial using encapsulated Islet cells," stated John Steel, Chairman and CEO of Islet Sciences. "We are pleased to announce this collaboration as we continue to add important Diabetes focused partners to our program."

"Our entire Science team is excited to work with Spring Point because of their commitment and vision for persons with Insulin dependent Diabetes," stated Dr. Jonathan Lakey, Chief Scientific Officer of Islet Sciences. "We are pleased to announce this strategic alliance with such a credible partner that can provide this unique capability."

"We are delighted to partner with Islet Sciences as they prepare for their upcoming clinical trials," stated Tom Spizzo, Executive Director of Spring Point Project. "Our team and facility have the exceptional capabilities needed to support such a trial as Islet Sciences implements their novel scientific approach."

About Spring Point Project

Spring Point Project, headquartered in Minneapolis, MN, is working to provide an unlimited source of pig islet cells to accelerate the availability and affordability of islet transplantation to cure diabetes. Spring Point Project works to provide the suitable pig islet source academia and the biotechnology industry required to move toward a cure for diabetes. For more information on Spring Point Project, visit www.SpringPointProject.org.

About Islet Sciences, Inc.

Islet Sciences is a development-stage biotechnology company with patented technologies focused on transplantation therapy for people with insulin-dependent diabetes.  The Company's transplantation technology includes methods for the culturing, isolation, maturation, and immunoprotection (microencapsulation) of islet cells. The Company's mission includes the introduction of commercial products with applications to cell-based replacement therapy in the healthcare marketplace. www.isletsciences.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements for Islet Sciences reflect current expectations, as of the date of this press release, and involve certain risks and uncertainties.   Actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors.  Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the risks described in the Islet Science's reports filed with the Securities and Exchange Commission.  The companies' further development is highly dependent on future medical and research developments and market acceptance, which is outside their control.

Investor Contact:
Jeff Ramson
ProActive Capital Group
(646) 863-6893
jramson@proactivecrg.com


'/>"/>
SOURCE Islet Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic
2. Caspase Inhibitor Enters Clinical Trial In Islet Transplantation As Treatment For Diabetes
3. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
4. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
7. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
8. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
9. Neurocrine Biosciences Reports First Quarter 2012 Results
10. Remedy Informatics Named "Cool Vendor" in Life Sciences by Leading Technology Analyst Firm
11. Effie Toshav Joins Fenwick - Broadens Life Sciences Service Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec. 1, 2016  Today, Simpson Healthcare Executives, ... honor of being selected as winners of multiple awards ... Executives Website at the PLATINUM level, Blue Zones Menu ... at the GOLD Level, and our proprietary 3ConneX Platform ... Simpson Healthcare Executives, we are excited to showcase our ...
(Date:12/2/2016)... Allergan plc (NYSE: AGN ), a ... previously announced Accelerated Share Repurchase (ASR) Program. Logo - ... ... previously announced, the Company entered into a variable tenor ASR ... repurchase $10 billion of its ordinary shares. Approximately 40.5 million ...
(Date:11/30/2016)... 2016 Research and Markets has announced the ... MedCore" report to their offering. ... , Detachable coil embolization is ... malformations. The detachable coil embolization treatment of cerebral aneurysms is less invasive ... weakened area in the wall of an artery in the brain. This ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... Center for Autism and Related Disorders (CARD) ... by autism spectrum disorder (ASD) and other developmental disabilities. The group, which is being ... and other caregivers the opportunity to share stories and advice, seek help, and continue ...
(Date:12/2/2016)... ... 02, 2016 , ... Dr. Raffi Hovsepian, a leading plastic, ... 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The prestigious ... experience, and professional associations. , One the most frequently honored surgeons in ...
(Date:12/2/2016)... ... December 02, 2016 , ... Universal Medical ... systems and the first company to offer robotic imaging to veterinary medicine is ... booth # 941 for the American Association of Equine Practitioners 62nd Annual Convention ...
(Date:12/2/2016)... San Francisco, CA (PRWEB) , ... December 02, ... ... in digitally-enabled care journeys, announced today that it has raised $6.0 million in ... are inspired by Clarify Health’s conviction that patients and their caregivers can receive ...
(Date:11/30/2016)... Massachusetts (PRWEB) , ... November 30, 2016 , ... ... proud to announce that we have been designated as a Cigna Infertility Center ... or exceed rigorous performance standards. , “It’s an honor to be designated ...
Breaking Medicine News(10 mins):